Ovarian Endometrioid Adenocarcinoma Completed Phase 2 Trials for Sargramostim (DB00020)

IndicationStatusPhase
DBCOND0028505 (Ovarian Endometrioid Adenocarcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00466960Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous ChemotherapyTreatment